Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01084837 | Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure(RENVEL) | completed | Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT00915408 | A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma(CRD) | completed | Phase 1 / Phase 2 | 32 | King's College Hospital NHS Trust |
| 1 |
| Sep 2, 2015 |
| clinicaltrials |
| NCT01085214 | AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2015 | clinicaltrials |
| NCT02221479 | Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma | completed | Phase 2 | 14 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 4, 2015 | clinicaltrials |
| NCT00131261 | Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma | completed | Phase 2 | 25 | Valerio TherapeuticsINDUSTRY | 4 | Jul 8, 2015 | clinicaltrials |
| NCT00083382 | Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide | completed | Phase 2 | 83 | University of ArkansasOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT01531998 | Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT00201695 | Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma | completed | Phase 2 | 12 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 10, 2015 | clinicaltrials |
| NCT02467010 | Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance(REMM) | completed | Phase 2 | 73 | University Medical Center GroningenOTHER | 1 | Jun 9, 2015 | clinicaltrials |
| NCT00998049 | Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant | completed | Phase 2 | 40 | Mayo ClinicOTHER | 1 | May 14, 2015 | clinicaltrials |
| NCT00778752 | Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma | completed | Phase 1 / Phase 2 | 24 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT01160484 | Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 40 | OncotherapeuticsINDUSTRY | 1 | May 4, 2015 | clinicaltrials |
| NCT00066638 | FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2015 | clinicaltrials |
| NCT00002849 | S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis | completed | Phase 2 | 93 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00809276 | Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | completed | Phase 1 / Phase 2 | 92 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT01849848 | Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 17 | SymBio PharmaceuticalsINDUSTRY | 1 | Feb 6, 2015 | clinicaltrials |
| NCT00908232 | Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD(SEQUENTIAL) | completed | Phase 2 | 163 | Janssen-Cilag International NVINDUSTRY | 10 | Jan 15, 2015 | clinicaltrials |
| NCT00833560 | A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy | completed | Phase 2 | 401 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Nov 21, 2014 | clinicaltrials |
| NCT00911859 | A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients | completed | Phase 2 | 118 | Janssen Research & Development, LLCINDUSTRY | 11 | Nov 18, 2014 | clinicaltrials |
| NCT00564200 | MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning(MINIALO-VELCAD) | completed | Phase 2 | 30 | PETHEMA FoundationOTHER | 1 | Oct 28, 2014 | clinicaltrials |
| NCT00505895 | FM 140 vs FM100 Study in Patients With Multiple Myeloma | completed | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2014 | clinicaltrials |
| NCT01095757 | Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection | completed | Phase 2 | 45 | Emory UniversityOTHER | 1 | Sep 29, 2014 | clinicaltrials |
| NCT00691704 | Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy | completed | Phase 2 | 18 | Cristina GasparettoOTHER | 1 | Aug 19, 2014 | clinicaltrials |
| NCT00972959 | Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy | completed | Phase 2 | 17 | University of AthensOTHER | 1 | Aug 5, 2014 | clinicaltrials |
| NCT00586014 | High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma | completed | Phase 2 | 91 | Duke UniversityOTHER | 0 | Jul 8, 2014 | clinicaltrials |
| NCT01096342 | Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 2 | Jun 18, 2014 | clinicaltrials |
| NCT01283776 | Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation(OCTET-CY) | completed | Phase 2 | 11 | University of CologneOTHER | 1 | Jun 10, 2014 | clinicaltrials |
| NCT00580034 | Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath | completed | Phase 2 | 176 | David Rizzieri, MDOTHER | 1 | Jun 3, 2014 | clinicaltrials |
| NCT00075881 | Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00597714 | Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant | completed | Phase 2 | 264 | David Rizzieri, MDOTHER | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00514137 | Sunitinib in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00872521 | A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma | completed | Phase 2 | 107 | Janssen-Cilag Pty LtdINDUSTRY | 1 | May 16, 2014 | clinicaltrials |
| NCT00402181 | An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 53 | Centocor, Inc.INDUSTRY | 2 | May 14, 2014 | clinicaltrials |
| NCT00431769 | An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma | completed | Phase 2 | 130 | Janssen-Cilag International NVINDUSTRY | 8 | May 12, 2014 | clinicaltrials |
| NCT00743288 | Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | OncotherapeuticsINDUSTRY | 1 | May 8, 2014 | clinicaltrials |
| NCT00901225 | Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant | completed | Phase 2 | 21 | Duke UniversityOTHER | 1 | May 7, 2014 | clinicaltrials |
| NCT01105403 | Exploratory Study on POL6326 in Stem Cell Mobilization | completed | Phase 2 | 21 | Polyphor Ltd.INDUSTRY | 1 | Apr 23, 2014 | clinicaltrials |
| NCT01220375 | PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma(PAV) | completed | Phase 2 | 44 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Apr 17, 2014 | clinicaltrials |
| NCT00847639 | Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma(07-REV) | completed | Phase 2 | 30 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Apr 4, 2014 | clinicaltrials |
| NCT00322387 | Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients | completed | Phase 2 | 40 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00322491 | Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients | completed | Phase 2 | 49 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00322842 | Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients | completed | Phase 2 | 35 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00396266 | AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF | completed | Phase 2 | 22 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00970021 | Agaricus Blazei Murill in Patients With Multiple Myeloma | completed | Phase 2 | 39 | Ullevaal University HospitalOTHER | 1 | Feb 25, 2014 | clinicaltrials |
| NCT00665314 | Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). | completed | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Feb 11, 2014 | clinicaltrials |
| NCT00750815 | Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 58 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 20, 2014 | clinicaltrials |
| NCT00617591 | Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) | completed | Phase 2 | 57 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 17, 2014 | clinicaltrials |
| NCT00205751 | Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy | completed | Phase 2 / Phase 3 | 350 | Austrian Forum Against CancerOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT01168804 | Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma(BBD) | completed | Phase 2 | 79 | Austrian Forum Against CancerOTHER | 2 | Nov 25, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Sep 17, 2015source: clinicaltrials